Literature DB >> 15169761

Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.

Mary Rucker1, Thomas J Fraites, Stacy L Porvasnik, Melissa A Lewis, Irene Zolotukhin, Denise A Cloutier, Barry J Byrne.   

Abstract

Several human genetic diseases that affect striated muscle have been modeled by creating knockout mouse strains. However, many of these are perinatal lethal mutations that result in death from respiratory distress within hours after birth. As the diaphragm muscle does not contract until birth, the sudden increase in diaphragm activity creates permanent injury to the muscle causing it to fail to meet respiratory demands. Therefore, the impact of these mutations remains hidden throughout embryonic development and early death prevents investigators from performing detailed studies of other striated muscle groups past the neonatal stage. Glycogen storage disease type II (GSDII), caused by a deficiency in acid alpha-glucosidase (GAA), leads to lysosomal accumulation of glycogen in all cell types and abnormal myofibrillogenesis in striated muscle. Contractile function of the diaphragm muscle is severely affected in both infantile-onset and late-onset individuals, with death often resulting from respiratory failure. The knockout mouse model of GSDII survives well into adulthood despite the gradual weakening of all striated muscle groups. Using this model, we investigated the delivery of recombinant adeno-associated virus (rAAV) vectors encoding the human GAA cDNA to the developing embryo. Results indicate specific high-level transduction of diaphragm tissue, leading to activity levels up to 10-fold higher than normal and restoration of normal contractile function. Up to an estimated 50 vector copies per diploid genome were quantified in treated diaphragms. Histological glycogen staining of treated diaphragms revealed prevention of lysosomal glycogen accumulation in almost all fibers when compared with untreated controls. This method could be employed with disease models where specific rescue of the diaphragm would allow for increased survival and thus further investigation into the impact of the gene deletion on other striated muscle groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169761     DOI: 10.1242/dev.01169

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  25 in total

1.  Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.

Authors:  Kai Qiu; Darin J Falk; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease.

Authors:  Cathryn S Mah; Darin J Falk; Sean A Germain; Jeffry S Kelley; Melissa A Lewis; Denise A Cloutier; Lara R DeRuisseau; Thomas J Conlon; Kerry O Cresawn; Thomas J Fraites; Martha Campbell-Thompson; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2010-01-26       Impact factor: 11.454

Review 3.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

4.  Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.

Authors:  Thomas J Conlon; Cathryn S Mah; Christina A Pacak; Mary B Rucker Henninger; Kirsten E Erger; Marda L Jorgensen; C Chang I Lee; Alice F Tarantal; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2016-12       Impact factor: 5.032

5.  Genetic modification of airway progenitors after lentiviral gene delivery to the amniotic fluid of murine fetuses.

Authors:  Suparna Mishra; Xingchao Wang; Nancy Smiley; Ping Xia; Chang Mu Hong; Dinithi Senadheera; Kim Chi Bui; Carolyn Lutzko
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-25       Impact factor: 6.914

6.  Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy.

Authors:  Jennifer M Peterson; William Kline; Benjamin D Canan; Daniel J Ricca; Brian Kaspar; Dawn A Delfín; Kelly DiRienzo; Paula R Clemens; Paul D Robbins; Albert S Baldwin; Pat Flood; Pravin Kaumaya; Michael Freitas; Joe N Kornegay; Jerry R Mendell; Jill A Rafael-Fortney; Denis C Guttridge; Paul M L Janssen
Journal:  Mol Med       Date:  2011-01-20       Impact factor: 6.354

Review 7.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

Review 8.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

9.  Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene.

Authors:  B M Koppanati; J Li; D P Reay; B Wang; M Daood; H Zheng; X Xiao; J F Watchko; P R Clemens
Journal:  Gene Ther       Date:  2010-06-10       Impact factor: 5.250

10.  Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver.

Authors:  Katsuya Inagaki; Chuncheng Piao; Nicole M Kotchey; Xiaolin Wu; Hiroyuki Nakai
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.